Circular RNA circCDK13 suppresses cell proliferation, migration and invasion by modulating the JAK/STAT and PI3K/AKT pathways in liver cancer

Lin,Qu; Ling,Yun-Biao; Chen,Jun-Wei; Zhou,Chu-Ren; Chen,Jie; Li,Xing; Huang,Ming-Sheng

doi:10.3892/ijo.2018.4371

Circular RNA circCDK13 suppresses cell proliferation, migration and invasion by modulating the JAK/STAT and PI3K/AKT pathways in liver cancer

Authors:
- Qu Lin
- Yun-Biao Ling
- Jun-Wei Chen
- Chu-Ren Zhou
- Jie Chen
- Xing Li
- Ming-Sheng Huang
View Affiliations

Affiliations: Department of Medical Oncology, Τhe Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510630, P.R. China, Guangdong Key Laboratory of Liver Disease Research, Τhe Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510630, P.R. China
Published online on: April 12, 2018 https://doi.org/10.3892/ijo.2018.4371
Pages: 246-256

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Circular RNAs have recently been disclosed as potential biomarkers for human cancers. This study aimed to characterize the expression and function of a novel circular RNA, circCDK13, in liver cancer progression, as well as to elucide the underlying mechanisms. For this purpose, circCDK13 expression was quantitatively analyzed by RT-PCR in various liver cancer cell lines and human cancerous tissues. The migration, cell cycle progression, proliferation and invasion of liver cancer cells with an enhanced circCDK13 expression were evaluated by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay, flow cytometry and the Transwell culture system. Microarray and western blot analyses were performed to explore the underlying signaling mechanisms. The role of circCDK13 in liver cancer was finally examined by tumorigenicity assay using nude mice. The results revealed that circCDK13 expression was suppressed in various liver cancer lines and tissue samples from patients with liver cancer (hepatocellular carcinoma). The induced overexpression of circCDK13 in the liver cancer cells markedly inhibited their migration rates, altered cell cycle progression, and suppressed the cell migratory and invasive capacities. Microarray analysis also identified numerous downstream genes regulated by circCDK13, particularly those in the Janus tyrosine kinase (JAK)/signal transducer and activator of transcription (STAT) and phosphoinositide 3-kinase (PI3K)/AKT signaling pathways. The results of the tumorigenicity assay revealed that circCDK13 overexpression significantly inhibited liver cancer progression in nude mice. On the whole, the findings of this study indicate that circCDK13 is a novel circular RNA that suppresses liver cancer progression, and that these suppressive effects are possibly mediated via the JAK/STAT and PI3K/AKT signaling pathways.

View Figures

View References

1	Perz JF, Armstrong GL, Farrington LA, Hutin YJ and Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 45:529–538. 2006. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
3	Clark T, Maximin S, Meier J, Pokharel S and Bhargava P: Hepatocellular carcinoma: Review of epidemiology, screening, imaging diagnosis, response assessment, and treatment. Curr Probl Diagn Radiol. 44:479–486. 2015. View Article : Google Scholar : PubMed/NCBI
4	Hsueh CT, Liu D and Wang H: Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials. Biomark Res. 1:12013. View Article : Google Scholar : PubMed/NCBI
5	Xu JB, Qi FZ, Xu G, Chen GF, Qin LX and Zhang JH: Value of alpha-fetoprotein and clinical characteristics in patients with liver neoplasm. Neoplasma. 61:218–224. 2014. View Article : Google Scholar
6	Prieto De Paula JM, Mayor Toranzo E, Gallardo Borge L and Franco Hidalgo S: Small-cell lung cancer and elevated CA 19.9 tumor marker levels. Arch Bronconeumol. 48:385–386. 2012.In Spanish. View Article : Google Scholar : PubMed/NCBI
7	Zhang HX, Liu DD, Jin BJ, Wang YW, Liu Q, Duan RB, Zhao P and Ma MX: Changes of serum trace elements, AFP, CEA, SF, T3, T4 and IGF-II in different periods of rat liver cancer. Chin J Cancer Res. 23:301–305. 2011. View Article : Google Scholar
8	Zhang D, Yu M, Xu T and Xiong B: Predictive value of serum CEA, CA19-9 and CA125 in diagnosis of colorectal liver metastasis in Chinese population. Hepatogastroenterology. 60:1297–1301. 2013.PubMed/NCBI
9	Benowitz S: Liver cancer biomarkers struggling to succeed. J Natl Cancer Inst. 99:590–591. 2007. View Article : Google Scholar : PubMed/NCBI
10	Dong Y, He D, Peng Z, Peng W, Shi W, Wang J, Li B, Zhang C and Duan C: Circular RNAs in cancer: An emerging key player. J Hematol Oncol. 10:22017. View Article : Google Scholar : PubMed/NCBI
11	Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK and Kjems J: Natural RNA circles function as efficient microRNA sponges. Nature. 495:384–388. 2013. View Article : Google Scholar : PubMed/NCBI
12	Sanger HL, Klotz G, Riesner D, Gross HJ and Kleinschmidt AK: Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc Natl Acad Sci USA. 73:3852–3856. 1976. View Article : Google Scholar : PubMed/NCBI
13	Li J, Yang J, Zhou P, Le Y, Zhou C, Wang S, Xu D, Lin HK and Gong Z: Circular RNAs in cancer: Novel insights into origins, properties, functions and implications. Am J Cancer Res. 5:472–480. 2015.PubMed/NCBI
14	Wang Y, Mo Y, Gong Z, Yang X, Yang M, Zhang S, Xiong F, Xiang B, Zhou M, Liao Q, et al: Circular RNAs in human cancer. Mol Cancer. 16:252017. View Article : Google Scholar : PubMed/NCBI
15	Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, Marzluff WF and Sharpless NE: Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 19:141–157. 2013. View Article : Google Scholar :
16	Salzman J, Gawad C, Wang PL, Lacayo N and Brown PO: Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS One. 7:e307332012. View Article : Google Scholar : PubMed/NCBI
17	Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, Zhong G, Yu B, Hu W, Dai L, et al: Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 22:256–264. 2015. View Article : Google Scholar : PubMed/NCBI
18	Granados-Riveron JT and Aquino-Jarquin G: The complexity of the translation ability of circRNAs. Biochim Biophys Acta. 1859:1245–1251. 2016. View Article : Google Scholar : PubMed/NCBI
19	Greene J, Baird AM, Brady L, Lim M, Gray SG, McDermott R and Finn SP: Circular RNAs: Biogenesis, Function and Role in Human Diseases. Front Mol Biosci. 4:382017. View Article : Google Scholar : PubMed/NCBI
20	Ren S, Xin Z, Xu Y, Xu J and Wang G: Construction and analysis of circular RNA molecular regulatory networks In liver cancer. Cell Cycle. 16:2204–2211. 2017. View Article : Google Scholar : PubMed/NCBI
21	Bai F, Yano Y, Fukumoto T, Takebe A, Tanaka M, Kuramitsu K, Anggorowati N, Rinonce HT, Widasari DI, Saito M, et al: Quantification of pregenomic RNA and covalently closed circular DNA in hepatitis B virus-related hepatocellular carcinoma. Int J Hepatol. 2013:8492902013. View Article : Google Scholar
22	Qin M, Liu G, Huo X, Tao X, Sun X, Ge Z, Yang J, Fan J, Liu L and Qin W: Hsa_circ_0001649: A circular RNA and potential novel biomarker for hepatocellular carcinoma. Cancer Biomark. 16:161–169. 2016. View Article : Google Scholar
23	Shang X, Li G, Liu H, Li T, Liu J, Zhao Q and Wang C: Comprehensive circular RNA profiling reveals that hsa_circ_0005075, a new circular RNA biomarker, is involved in hepatocellular carcinoma development. Medicine (Baltimore). 95:e38112016. View Article : Google Scholar
24	Fu L, Yao T, Chen Q, Mo X, Hu Y and Guo J: Screening differential circular RNA expression profiles reveals hsa_circ_0004018 is associated with hepatocellular carcinoma. Oncotarget. 8:58405–58416. 2017.PubMed/NCBI
25	Huang XY, Huang ZL, Xu YH, Zheng Q, Chen Z, Song W, Zhou J, Tang ZY and Huang XY: Comprehensive circular RNA profiling reveals the regulatory role of the circRNA-100338/miR-141-3p pathway in hepatitis B-related hepatocellular carcinoma. Sci Rep. 7:54282017. View Article : Google Scholar : PubMed/NCBI
26	Greifenberg AK, Hönig D, Pilarova K, Düster R, Bartholomeeusen K, Bösken CA, Anand K, Blazek D and Geyer M: Structural and functional analysis of the Cdk13/Cyclin K complex. Cell Rep. 14:320–331. 2016. View Article : Google Scholar : PubMed/NCBI
27	Even Y, Escande ML, Fayet C and Genevière AM: CDK13, a kinase involved in Pre-mRNA splicing, is a component of the perinucleolar compartment. PLoS One. 11:e01491842016. View Article : Google Scholar : PubMed/NCBI
28	Kim HE, Kim DG, Lee KJ, Son JG, Song MY, Park YM, Kim JJ, Cho SW, Chi SG, Cheong HS, et al: Frequent amplification of CENPF, GMNN and CDK13 genes in hepatocellular carcinomas. PLoS One. 7:e432232012. View Article : Google Scholar : PubMed/NCBI
29	Glažar P, Papavasileiou P and Rajewsky N: circBase: A database for circular RNAs. RNA. 20:1666–1670. 2014. View Article : Google Scholar
30	Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, et al: Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 495:333–338. 2013. View Article : Google Scholar : PubMed/NCBI
31	Rybak-Wolf A, Stottmeister C, Glažar P, Jens M, Pino N, Giusti S, Hanan M, Behm M, Bartok O, Ashwal-Fluss R, et al: Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. Mol Cell. 58:870–885. 2015. View Article : Google Scholar : PubMed/NCBI
32	Salzman J, Chen RE, Olsen MN, Wang PL and Brown PO: Cell-type specific features of circular RNA expression. PLoS Genet. 9:e10037772013. View Article : Google Scholar : PubMed/NCBI
33	Thomas M: Molecular targeted therapy for hepatocellular carcinoma. J Gastroenterol. 44(Suppl 19): 136–141. 2009. View Article : Google Scholar : PubMed/NCBI
34	Tang H, Li RP, Liang P, Zhou YL and Wang GW: miR-125a inhibits the migration and invasion of liver cancer cells via suppression of the PI3K/AKT/mTOR signaling pathway. Oncol Lett. 10:681–686. 2015. View Article : Google Scholar : PubMed/NCBI
35	Wilson GS, Tian A, Hebbard L, Duan W, George J, Li X and Qiao L: Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro. Cancer Lett. 341:224–230. 2013. View Article : Google Scholar : PubMed/NCBI
36	Sun ZJ, Chen G, Hu X, Zhang W, Liu Y, Zhu LX, Zhou Q and Zhao YF: Activation of PI3K/Akt/IKK-α/NF-kappaB signaling pathway is required for the apoptosis-evasion in human salivary adenoid cystic carcinoma: Its inhibition by quercetin. Apoptosis. 15:850–863. 2010. View Article : Google Scholar : PubMed/NCBI
37	Booz GW, Day JN and Baker KM: Interplay between the cardiac renin angiotensin system and JAK-STAT signaling: Role in cardiac hypertrophy, ischemia/reperfusion dysfunction, and heart failure. J Mol Cell Cardiol. 34:1443–1453. 2002. View Article : Google Scholar : PubMed/NCBI
38	Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI and Boyd J: Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res. 11:2875–2878. 2005. View Article : Google Scholar : PubMed/NCBI
39	Or YY, Hui AB, Tam KY, Huang DP and Lo KW: Characterization of chromosome 3q and 12q amplicons in nasopharyngeal carcinoma cell lines. Int J Oncol. 26:49–56. 2005.
40	Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang QC, Zhang YJ, Lu R, Chen YX and Fang JY: Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia. 10:287–297. 2008. View Article : Google Scholar : PubMed/NCBI
41	Li F, Zhang L, Li W, Deng J, Zheng J, An M, Lu J and Zhou Y: Circular RNA ITCH has inhibitory effect on ESCC by suppressing the Wnt/β-catenin pathway. Oncotarget. 6:6001–6013. 2015.
42	Simile MM, Latte G, Demartis MI, Brozzetti S, Calvisi DF, Porcu A, Feo CF, Seddaiu MA, Daino L, Berasain C, et al: Post-translational deregulation of YAP1 is genetically controlled in rat liver cancer and determines the fate and stem-like behavior of the human disease. Oncotarget. 7:49194–49216. 2016. View Article : Google Scholar : PubMed/NCBI
43	O'Shea JJ, Gadina M and Schreiber RD: Cytokine signaling in 2002: New surprises in the Jak/Stat pathway. Cell. 109(Suppl 1): S121–S131. 2002. View Article : Google Scholar
44	Arumuggam N, Bhowmick NA and Rupasinghe HP: A Review: Phytochemicals targeting JAK/STAT signaling and IDO expression in cancer. Phytother Res. 29:805–817. 2015. View Article : Google Scholar : PubMed/NCBI
45	Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
46	Lin CW, Chang YL, Chang YC, Lin JC, Chen CC, Pan SH, Wu CT, Chen HY, Yang SC, Hong TM, et al: MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1. Nat Commun. 4:18772013. View Article : Google Scholar : PubMed/NCBI
47	He Y and Liu X: The tumor-suppressor gene LZTS1 suppresses hepatocellular carcinoma proliferation by impairing PI3K/Akt pathway. Biomed Pharmacother. 76:141–146. 2015. View Article : Google Scholar : PubMed/NCBI